Sitemap
Every page on the Systemix Health website, grouped by section.
Client results
- Reading adoption risk before launch in an established treatment field
- When the intelligence says stop
- Choosing the next indication on ecosystem readiness, not internal familiarity
- Mapping the real decision unit across five European markets
- Country launch readiness for a newly EMA-approved oncology therapy
Insights
- FDA proposes one licence for many versions of a personalised gene-editing therapy
- Rare disease drug development is evolving. What does this mean for evidence strategies?
- EU pharma package: orphan exclusivity and HTA evidence
- FDA's new rare disease framework: What it means for drug developers
- Why we focus on product-system fit
- The Joint Clinical Assessment and rare disease
- How we measure ecosystem readiness